Table 1.
The detailed information and characteristics of breast tumors collected from patients the First Affiliated Hospital of China Medical University
| Variables | Metastasis (n=28) | Without metastasis (n=34) | p |
|---|---|---|---|
| Age(years) , n(%) | 0.816 | ||
| ≤ 50 | 19 (67.86) | 24 (70.59) | |
| >50 | 9 (32.14) | 10 (29.41) | |
| T stage, n(%) | 0.779 | ||
| T1 | 13 (46.4) | 17 (50.0) | |
| T2 | 15 (53.6) | 17 (50.0) | |
| Adjuvant therapy, n (%) | 0.705 | ||
| Chemotherapy | 19 (67.9) | 20 (58.8) | |
| Hormone therapy | 27 (96.4) | 34 (100.0) | |
| Molecular subtyping,n(%) | 0.424 | ||
| Luminal A | 8 (28.6) | 13 (38.24) | |
| Luminal B | 20 (71.4) | 21 (61.76) | |
| Histotype ,n(%) | 0.737 | ||
| IDC | 23 (82.1) | 29 (85.29) | |
| rests (ILC, DCIS-MI, mucinous carcinoma) | 5 (17.9) | 5 (14.71) | |
| Metastatic sites, n(%) | NA | ||
| Lung metastasis | 9 | NA | |
| osseous metastasis | 12 | NA | |
| hepatic metastases | 7 | NA | |
| Follow-up time (months) | <0.001 | ||
| Min-Max | 6-86 | 59-131 | |
| Median | 46 | 81 |
Note: Luminal A: ER and PR positive (≥1%) , HER-2 negative, Ki67 low expression (<14%,) ; Luminal B: ER or PR positive (≥1%), HER-2 negative, Ki67 high expression (≥14%). NA, Not Applicable.